Cited by 1,548Inflammatory Bowel DiseaseOcular Diseases and Behçet’s SyndromeMicroscopic Colitis

The DOI matches its Crossref record; 483 of the 495 references it cites were found in a registry or an index.

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Dignass, Axel, Lindsay, James O., Sturm, Andreas, Windsor, Alastair, Colombel, Jean-Frederic, Allez, Mathieu, D'Haens, Gert, D'Hoore, André, Mantzaris, Gerassimos, Novacek, Gottfried, Öresland, Tom, Reinisch, Walter, Sans, Miquel, Stange, Eduard, Vermeire, Severine, Travis, Simon, Van Assche, Gert·2012·Journal of Crohn's and Colitis

DOI 10.1016/j.crohns.2012.09.002

Open this paper in CoChat — free account

Abstract

### 5.1 General When deciding the appropriate treatment strategy for active ulcerative colitis one should consider the activity, distribution (proctitis, left-sided, extensive1), and pattern of disease. The disease pattern includes relapse frequency, course of disease, response to previous medications, side-effect profile of medication and extra-intestinal manifestations. The age at onset and disease duration may also be important factors. #### 5.1.1 Disease activity The principal disease activity scoring systems used in clinical trials are covered in Section 1.2 and have been comprehensively reviewed.2 However there are some practical points that are relevant for routine clinical use. For example, it is most important to distinguish patients with severe ulcerative colitis necessitating hospital admission from those with mild or moderately active disease who can generally be managed as outpatients. The simplest, best validated and most widely used index for identifying severe UC remains that of Truelove and Witts3: any patient who has a bloody stool frequency ≥ 6/day and a tachycardia (> 90 bpm), or temperature > 37.8 °C, or anaemia (haemoglobin 30 mm/h) has severe ulcerative colitis (Table 1.3). Only one additional criterion in addition to the bloody stool frequency ≥ 6/day is needed to define a severe attack.4,5 It should be standard practice to confirm the presence of active colitis by sigmoidoscopy before starting treatment. Flexible sigmoidoscopy and biopsy may exclude unexpected causes of symptoms that mimic active disease such as cytomegalovirus colitis, rectal mucosal prolapse, Crohn's disease, malignancy, or even irritable bowel syndrome and haemorrhoidal bleeding. There may be a significant overlap between other diseases that mimic ulcerative colitis and the broad spectrum of UC damage.6,7 In addition, all patients with active disease require stool cultures with Clostridium difficile toxin assay to exclude enteric infection. Patients with an appropriate …

Integrity signals

Registry

Crossref · 10.1016/j.crohns.2012.09.002

Cites

483 of 483 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
Rutgeerts, P. J., Sandborn, W. J., Feagan, B. G., Reinisch, W., Olson, A. D., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S. B., Lichtenstein, G. R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050516 · Cited by 3,910
Self-citation
Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology
Silverberg, M. S., Satsangi, J., Ahmad, T., Arnott, I. D., Bernstein, C. N., Brant, S. R., Caprilli, R., Colombel, J., Gasché, C., Geboes, K., et al. (2005) · Canadian Journal of Gastroenterology · doi:10.1155/2005/269076 · Cited by 3,410
Self-citation
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
Colombel, J., Sandborn, W. J., Reinisch, W., Mantzaris, G. J., Kornbluth, A. A., Rachmilewitz, D., Lichtiger, S., D’Haens, G., Diamond, R. H., Broussard, D. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0904492 · Cited by 3,184
Self-citation
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Feagan, B. G., Rutgeerts, P. J., Sands, B. E., Hanauer, S. B., Colombel, J., Sandborn, W. J., Assche, G. V., Axler, J. L., Kim, H. J., Danese, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215734 · Cited by 2,892
Self-citation
Cortisone in Ulcerative Colitis
Truelove, S. C., & Witts, L. J. (1955) · BMJ · doi:10.1136/bmj.2.4947.1041 · Cited by 2,793
Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Assche, G. V., Haens, G. D., Carbonez, A., & Rutgeerts, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,012
Self-citation
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy
Lichtiger, S., Present, D. H., Kornbluth, A. A., Gelernt, I. M., Bauer, J. J., Galler, G. W., Michelassi, F., & Hanauer, S. B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302601 · Cited by 1,715
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
Dignass, A. U., Assche, G. V., Lindsay, J. O., Lémann, M., Söderholm, J. D., Colombel, J., Danese, S., D’Hoore, A., Gassull, M. À., Gomollón, F., et al. (2010) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,508
Self-citation
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine
Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M. A., Weismueller, J., Beglinger, C., Stolte, M., et al. (2004) · Gut · doi:10.1136/gut.2003.037747 · Cited by 1,285
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
Sandborn, W. J., Assche, G. V., Reinisch, W., Colombel, J., D’Haens, G., Wolf, D. C., Kron, M., Tighe, M. B., Lazar, A., & Thakkar, R. B. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.10.032 · Cited by 1,268
Self-citation

Flagged first, then by citations

Show all 495 references

12 of the 495 references couldn’t be matched to a known paper.

Research works printed but not linked: 6

Ferrante, 2009, Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis, Inflamm Bowel Dis, 15, 1062, 10.1002/ibd.20863 · DOI
Bojic, 2005, Pattern and outcome of severe ulcerative colitis: 15 year data, Gut, 54, A155
Hanauer, 2007, AGA Institute Consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, Gastroenterology, 133, 312
Miner, 1994, The effect of varying dose intervals of mesalamine enemas for the prevention of relapse in distal ulcerative colitis. Gastroenterology 1994;106: A736, Gastroenterology, 106, A736
Sandborn, 2009, Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab, Gastroenterology, 137, 1250, 10.1053/j.gastro.2009.06.061 · DOI
Manosa, 2009, Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis, Digestion, 80, 30, 10.1159/000212075 · DOI

Sorted by citations

Items 101–200 of 1,000

Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future
Pugliese, D., Felice, C., Papa, A., Gasbarrini, A., Rapaccini, G. L., Guidi, L., & Armuzzi, A. (2016) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1243468 · Cited by 120
Understanding and Minimising Injection-Site Pain Following Subcutaneous Administration of Biologics: A Narrative Review
Jones, A. S. C., Prignano, F., Gonçalves, J., Paul, M., & Sewerin, P. (2020) · Rheumatology and Therapy · doi:10.1007/s40744-020-00245-0 · Cited by 124
Multifunctional hydrogels based on chitosan, hyaluronic acid and other biological macromolecules for the treatment of inflammatory bowel disease: A review
Ouyang, Y., Zhao, J., & Wang, S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.12.032 · Cited by 120
Rhamnogalacturonan, a chemically-defined polysaccharide, improves intestinal barrier function in DSS-induced colitis in mice and human Caco-2 cells
Ferreira, D. M., Nascimento, A. M., Cipriani, T. R., Santana-Filho, A. P., Watanabe, P. D. S., ́Ana, D. D. M. G. S., Luciano, F. B., Bocate, K. P., van den Wijngaard, R. M., Werner, M. F. D. P., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-30526-2 · Cited by 118
New biologics and small molecules in inflammatory bowel disease: an update
Sabino, J., Verstockt, B., Vermeire, S., & Ferrante, M. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819853208 · Cited by 121
Self-citation
An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis
Ferretti, F., Cannatelli, R., Monico, M. C., Maconi, G., & Ardizzone, S. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092302 · Cited by 118
Management of Paediatric Ulcerative Colitis, Part 2: Acute Severe Colitis-An Evidence-based Consensus Guideline From the European Crohn's and Colitis Organization and the European Society of Paediatric Gastroenterology, Hepatology and Nutrition
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronský, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C., et al. (2018) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-165384 · Cited by 117
Relapse after withdrawal from anti‐ TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
Kennedy, N. A., Warner, B. D., Johnston, E., Flanders, L., Hendy, P., Ding, N. S., Harris, R. J., Fadra, A., Basquill, C., Lamb, C. A., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13547 · Cited by 116
Self-citation
Diets enriched with cranberry beans alter the microbiota and mitigate colitis severity and associated inflammation
Monk, J. M., Lepp, D., Zhang, C. P., Wu, W., Zarepoor, L., Lu, J. T., Pauls, K. P., Tsao, R., Wood, G. A., Robinson, L. E., et al. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2015.10.014 · Cited by 114
The current state of the art for biological therapies and new small molecules in inflammatory bowel disease
Paramsothy, S., Rosenstein, A. K., Mehandru, S., & Colombel, J. (2018) · Mucosal Immunology · doi:10.1038/s41385-018-0050-3 · Cited by 115
Self-citation
Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis - a double-blind, double-dummy study
Langhorst, J., Varnhagen, I., Schneider, S. B., Albrecht, U., Rueffer, A., Stange, R., Michalsen, A., & Dobos, G. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12397 · Cited by 113
Unexpected improvement in core autism spectrum disorder symptoms after long-term treatment with probiotics
Grossi, E., Melli, S., Dunca, D., & Terruzzi, V. (2016) · SAGE Open Medical Case Reports · doi:10.1177/2050313x16666231 · Cited by 122
Curcumin as a therapeutic agent for blocking NF-κB activation in ulcerative colitis
Wang, Y., Tang, Q.-C., Duan, P., & Yang, L. (2018) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2018.1469145 · Cited by 113
Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
Bek, S., Nielsen, J. V., Bojesen, A. B., Franke, A., Bank, S., Vogel, U. B., & Andersen, V. C. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13736 · Cited by 111
Review: Local Tumor Necrosis Factor-α Inhibition in Inflammatory Bowel Disease
Gareb, B., Otten, A. T., Frijlink, H. W., Dijkstra, G. D. H., & Kosterink, J. G. W. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060539 · Cited by 115
Inflammatory Bowel Disease and Colorectal Cancer: Epidemiology, Etiology, Surveillance, and Management
Sato, Y., Tsujinaka, S., Miura, T., Kitamura, Y., Suzuki, H., & Shibata, C. (2023) · Cancers · doi:10.3390/cancers15164154 · Cited by 111
Fecal microbiota transplantation in inflammatory bowel disease patients: A systematic review and meta-analysis
Caldeira, L. D. F., Borba, H. H. L., Tonin, F. S., Wiens, A., Fernández-Llimós, F., & Pontarolo, R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0238910 · Cited by 108
Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study
Vermeire, S., Chiorean, M. V., Panés, J., Peyrin‐Biroulet, L., Zhang, J., Sands, B. E., Lazin, K., Klassen, P., Naik, S. U., Cabell, C. H., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab016 · Cited by 114
Self-citation
Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis
Losurdo, G., Iannone, A., Contaldo, A., Ierardi, E., Leo, A. D., & Principi, M. (2015) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld.2014.1121.244.ecn · Cited by 109
The Effect of Disease Activity on Birth Outcomes in a Nationwide Cohort of Women with Moderate to Severe Inflammatory Bowel Disease
Kammerlander, H., Nielsen, J., Kjeldsen, J., Knudsen, T., Friedman, S., & Nørgård, B. M. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001102 · Cited by 108
Management of Inflammatory Bowel Disease in the Elderly Patient
Ananthakrishnan, A. N., Donaldson, T., Lasch, K. L., & Yajnik, V. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001099 · Cited by 108
Dietary intake of patients with inflammatory bowel disease: A comparison with individuals from a general population and associations with relapse
Opstelten, J. L., de Vries, J. H. M., Wools, A., Siersema, P. D., Oldenburg, B., & Witteman, B. J. M. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2018.06.983 · Cited by 108
Delphi consensus statement: Quality indicators for Inflammatory Bowel Disease Comprehensive Care Units
Calvet, X., Panés, J., Alfaro, N., Hinojosa, J., Sicilia, B., Gallego, M., Pérez, I., Mercado, P. L. Y. D., & Gomollón, F. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.10.010 · Cited by 107
The use of fecal calprotectin as a biomarker in gastrointestinal disease
Burri, E., & Beglinger, C. (2013) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2014.869476 · Cited by 107
Ulcerative Colitis Care Pathway
Dassopoulos, T., Cohen, R. D., Scherl, E., Schwartz, R. M., Kosinski, L. R., & Regueiro, M. D. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.036 · Cited by 106
Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease
Marsal, J., Acosta, M. B., Blumenstein, I., Cappello, M., Bazin, T., & Sebastian, S. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.897936 · Cited by 114
Future directions in inflammatory bowel disease management
D’Haens, G., Sartor, R. B., Silverberg, M. S., Petersson, J. H., & Rutgeerts, P. J. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.02.025 · Cited by 108
Self-citation
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
Chaparro, M., Garre, A., Mesonero, F., Rodríguez, C., Acosta, M. B., Martínez-Cadilla, J., Arroyo, M., Manceñido, N., Sierra‐Ausín, M., Vera‐Mendoza, I., et al. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa145 · Cited by 104
Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures
Fuméry, M., de Chambrun, G. P., Stéfanescu, C., Buisson, A., Bressenot, A., Beaugerie, L., Amiot, A., Altwegg, R., Savoye, G., Abitbol, V., et al. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.04.185 · Cited by 103
Increased Risk of Acute Myeloid Leukemias and Myelodysplastic Syndromes in Patients Who Received Thiopurine Treatment for Inflammatory Bowel Disease
Lopez, A., Mounier, M., Bouvier, A., Carrat, F., Maynadié, M., Beaugerie, L., & Peyrin‐Biroulet, L. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.026 · Cited by 106
Vegetarian or gluten‐free diets in patients with inflammatory bowel disease are associated with lower psychological well‐being and a different gut microbiota, but no beneficial effects on the course of the disease
Schreiner, P., Yılmaz, B., Rossel, J., Franc, Y., Misselwitz, B., Scharl, M. M., Zeitz, J., Frei, P., Greuter, T., Vavricka, S. R., et al. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619841249 · Cited by 103
The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases
Kim, H., Alten, R., Avedano, L., Dignass, A. U., Gomollón, F., Greveson, K., Halfvarson, J., Irving, P. M., Jahnsen, J., Lakatos, P. L., et al. (2020) · Drugs · doi:10.1007/s40265-020-01256-5 · Cited by 103
Self-citation
Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease
Olivieri, I., Cantini, F., Castiglione, F., Felice, C., Gionchetti, P., Orlando, A., Salvarani, C., Scarpa, R., Vecchi, M. L., & Armuzzi, A. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.04.003 · Cited by 103
Risks of Inflammatory Bowel Disease Treatment with Glucocorticosteroids and Aminosalicylates
Curkovic, I., Egbring, M., & Kullak-Ublick, G. A. (2013) · Digestive Diseases · doi:10.1159/000354699 · Cited by 105
Cooked navy and black bean diets improve biomarkers of colon health and reduce inflammation during colitis
Zhang, C., Monk, J. M., Lu, J. T., Zarepoor, L., Wu, W., Liu, R., Pauls, K. P., Wood, G. A., Robinson, L. E., Tsao, R., et al. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114513004352 · Cited by 103
Review article: the practical management of acute severe ulcerative colitis
Seah, D., & Cruz, P. P. D. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13491 · Cited by 102
The role of the gut microbiota in the treatment of inflammatory bowel diseases
Aggeletopoulou, I., Konstantakis, C., Assimakopoulos, S. F., & Triantos, C. K. (2019) · Microbial Pathogenesis · doi:10.1016/j.micpath.2019.103774 · Cited by 107
DUOX2 and DUOXA2 Form the Predominant Enzyme System Capable of Producing the Reactive Oxygen Species H2O2 in Active Ulcerative Colitis and are Modulated by 5-Aminosalicylic Acid
MacFie, T. S., Poulsom, R., Parker, A., Warnes, G., Boitsova, T., Nijhuis, A. M., Suraweera, N., Poehlmann, A., Szary, J., Feakins, R. M., et al. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000442012.45038.0e · Cited by 103
Self-citation
Cost-effectiveness of Telemedicine-directed Specialized vs Standard Care for Patients With Inflammatory Bowel Diseases in a Randomized Trial
de Jong, M. J., Boonen, A. E. R. C. H., Jong, A. E. V. D. M., Romberg-Camps, M. J. L., Bodegraven, A. A. V., Mahmmod, N., Markus, T., Dijkstra, G. D. H., Winkens, B., van Tubergen, A. M., et al. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.04.038 · Cited by 100
Nutrition and Supplementation in Ulcerative Colitis
Radziszewska, M., Smarkusz-Zarzecka, J., Ostrowska, L., & Pogodziński, D. (2022) · Nutrients · doi:10.3390/nu14122469 · Cited by 113
Mobile Phone Apps for Inflammatory Bowel Disease Self-Management: A Systematic Assessment of Content and Tools
Con, D., & Cruz, P. P. D. (2016) · JMIR mhealth and uhealth · doi:10.2196/mhealth.4874 · Cited by 99
Time to clinical response and remission for therapeutics in inflammatory bowel diseases: What should the clinician expect, what should patients be told?
Vasudevan, A., Gibson, P. R., & van Langenberg, D. R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i35.6385 · Cited by 97
Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
D’Amico, F., Parigi, T. L., Fiorino, G., Peyrin‐Biroulet, L., & Danese, S. (2019) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284819848631 · Cited by 96
H2S‐Releasing Versatile Montmorillonite Nanoformulation Trilogically Renovates the Gut Microenvironment for Inflammatory Bowel Disease Modulation
Jin, T., Lu, H., Zhou, Q., Chen, D., Zeng, Y., Shi, J., Zhang, Y., Wang, X., Shen, X., & Cai, X. (2024) · Advanced Science · doi:10.1002/advs.202308092 · Cited by 96
Association Between 6-Thioguanine Nucleotides Levels and Clinical Remission in Inflammatory Disease
Carla-Moreau, A., Paul, S., Tedesco, É. D., Rinaudo-Gaujous, M., Boukhadra, N., Genin, C., Peyrin‐Biroulet, L., & Roblin, X. (2014) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000439068.71126.00 · Cited by 95
The Historical Role and Contemporary Use of Corticosteroids in Inflammatory Bowel Disease
Dorrington, A., Selinger, C. P., Parkes, G. C., Smith, M. A., Pollok, R., & Raine, T. (2020) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaa053 · Cited by 96
Elderly patients and inflammatory bowel disease
Nimmons, D. (2016) · World Journal of Gastrointestinal Pharmacology and Therapeutics · doi:10.4292/wjgpt.v7.i1.51 · Cited by 94
Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period
Iacucci, M., Cannatelli, R., Labarile, N., Mao, R., Panaccione, R., Danese, S., Kochhar, G. S., Ghosh, S. K., & Shen, B. (2020) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(20)30119-9 · Cited by 94
Nanotechnology in the treatment of inflammatory bowel diseases
Viscido, A., Capannolo, A., Latella, G., Caprilli, R., & Frieri, G. (2014) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2014.02.024 · Cited by 94
Review article: dose optimisation of infliximab for acute severe ulcerative colitis
Hindryckx, P., Novak, G., Casteele, N. V., Laukens, D., Parker, C. E., Shackelton, L. M., Narula, N., Khanna, R., Dulai, P. S., Levesque, B. G., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13913 · Cited by 94
Self-citation
Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review
Damião, A. O. M. C., de Azevedo, M. F. C., Carlos, A. D. S., Wada, M. Y., Marcolino, T., & Feitosa, F. D. C. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i9.1142 · Cited by 93
Therapeutic management of inflammatory bowel disease in real‐life practice in the current era of anti‐TNF agents: analysis of the French administrative health databases 2009–2014
Kirchgesner, J., Lemaître, M., Rudnichi, A., Racine, A., Zureik, M., Carbonnel, F., & Dray‐Spira, R. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13835 · Cited by 93
Mucosal Healing in Ulcerative Colitis – When Zero is Better
Carvalho, P. B., de Castro, F. D., Rosa, B. J. F., Moreira, M. J., & Cotter, J. B. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv180 · Cited by 92
Surgery in ulcerative colitis: When? How?
Gallo, G., Kotze, P. G., & Spinelli, A. (2018) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2018.05.017 · Cited by 92
Limited Risks of Major Congenital Anomalies in Children of Mothers With IBD and Effects of Medications
Ban, L., Tata, L. J., Fiaschi, L., & Card, T. R. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.09.061 · Cited by 92
Cholesterol sulfate alleviates ulcerative colitis by promoting cholesterol biosynthesis in colonic epithelial cells
Xu, D., Ma, R.-J., Ju, Y., Song, X., Niu, B., Hong, W., Wang, R., Qin, Y., Zhao, Z., Zhang, Y., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32158-7 · Cited by 91
Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease
Renna, S. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i29.9675 · Cited by 91
Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis
Herfarth, H. H., Barnes, E. L., Valentine, J. F., Hanson, J., Higgins, P., Isaacs, K. L., Jackson, S., Osterman, M. T., Anton, K., Ivanova, A., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.06.046 · Cited by 91
Probiotics in digestive diseases: focus on Lactobacillus GG.
Pace, F., Pace, M., & Quartarone, G. (2015) · PubMed · Cited by 89
Vedolizumab exposure levels and clinical outcomes in ulcerative colitis: determining the potential for dose optimisation
Osterman, M. T., Rosario, M., Lasch, K. L., Barocas, M., Wilbur, J. D., Dirks, N. L., & Gastonguay, M. R. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15113 · Cited by 90
Biomarkers in inflammatory bowel disease: a practical guide
Clough, J., Colwill, M., Poullis, A. P., Pollok, R., Patel, K., & Honap, S. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241251600 · Cited by 102
Risk Factors and Clinical Outcomes Associated with Cytomegalovirus Colitis in Patients with Acute Severe Ulcerative Colitis
Lee, H., Park, S. H., Kim, S., Kim, J., Choi, J., Lee, H. J., Kim, W. S., Lee, J.-M., Kwak, M. S., Hwang, S. W., et al. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000675 · Cited by 90
JAK inhibition in inflammatory bowel disease
Olivera, P. A., Danese, S., & Peyrin‐Biroulet, L. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1291342 · Cited by 89
Antioxidant Therapy in Inflammatory Bowel Diseases
Dziąbowska-Grabias, K., Sztanke, M., Zając, P., Celejewski, M., Kurek, K., Szkutnicki, S., Korga, P., Bulikowski, W., & Sztanke, K. (2021) · Antioxidants · doi:10.3390/antiox10030412 · Cited by 91
Initial Disease Course and Treatment in an Inflammatory Bowel Disease Inception Cohort in Europe
Burisch, J. M., Pedersen, N. K., Cukovic-Cavka, S., Turk, N., Kaimakliotis, I. P., Ďuricová, D., Shonová, O., Vind, I., Avnstrøm, S., Thorsgaard, N., et al. (2013) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000436277.13917.c4 · Cited by 88
Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease
Lamb, C. A., O’Byrne, S., Keir, M. E., & Butcher, E. C. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy060 · Cited by 88
Potential benefits of colostrum in gastrointestinal diseases
Brecchia, G. (2016) · Frontiers in Bioscience-Scholar · doi:10.2741/s467 · Cited by 87
Risk for Overall Infection with Anti-TNF and Anti-integrin Agents Used in IBD
Shah, E. D., Farida, J. P., Siegel, C. A., Chong, K., & MELMED, G. Y. (2017) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000001049 · Cited by 87
Fat-soluble Vitamin Deficiencies and Inflammatory Bowel Disease
Fabisiak, N., Fabisiak, A., Watała, C. W., & Fichna, J. (2017) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000000911 · Cited by 87
Human Cytomegalovirus and Autoimmune Diseases: Where Are We?
Gugliesi, F., Pasquero, S., Griffante, G., Scutera, S., Albano, C., Pacheco, S. F. C., Riva, G., Dell’Oste, V., & Biolatti, M. (2021) · Viruses · doi:10.3390/v13020260 · Cited by 87
Review article: why, when and how to de‐escalate therapy in inflammatory bowel diseases
Pariente, B., & Laharie, D. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12838 · Cited by 86
Differences in the management of pediatric and adult onset ulcerative colitis — lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis
Ruemmele, F. M., & Turner, D. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.10.006 · Cited by 86
De-escalation of immunomodulator and biological therapy in inflammatory bowel disease
Chapman, T., Gomes, C. F., Louis, E. J., Colombel, J., & Satsangi, J. (2019) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(19)30186-4 · Cited by 88
Self-citation
Inflammatory bowel disease, cancer and medication: Cancer risk in the Dutch population‐based IBDSL cohort
van den Heuvel, T. R. A., Wintjens, D., Jeuring, S. F. G., Wassink, M. H. H., Romberg-Camps, M. J. L., Oostenbrug, L. E., Sanduleanu, S., Hameeteman, W. M., Zeegers, M. P., Masclee, A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30183 · Cited by 85
Advances in Use of Endoscopy, Radiology, and Biomarkers to Monitor Inflammatory Bowel Diseases
Panés, J., Jairath, V., & Levesque, B. G. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.10.005 · Cited by 84
Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland
Bähler, C., Schoepfer, A. M., Vavricka, S. R., Brüngger, B., & Reich, O. (2017) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000000891 · Cited by 84
Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
Sands, B. E., Armuzzi, A., Marshall, J. K., Lindsay, J. O., Sandborn, W. J., Danese, S., Panés, J., Bressler, B. L., Colombel, J., Lawendy, N., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15555 · Cited by 84
Self-citation
Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: Rapid symptom resolution and improvements in quality of life
Probert, C. S., Dignass, A. U., Lindgren, S. C., Pool, M. O., & Marteau, P. R. (2013) · Journal of Crohn s and Colitis · doi:10.1016/j.crohns.2013.08.007 · Cited by 84
Self-citation
Disease Outcome of Ulcerative Colitis in an Era of Changing Treatment Strategies: Results from the Dutch Population-Based IBDSL Cohort
Jeuring, S. F. G., Bours, P. H. A., Zeegers, M. P., Ambergen, T., van den Heuvel, T. R. A., Romberg-Camps, M. J. L., Bodegraven, A. A. V., Oostenbrug, L. E., Breukink, S. O., Stassen, L. P. S., et al. (2015) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjv129 · Cited by 84
Systematic Review
Narula, N., Fine, M., Colombel, J., Marshall, J. K., & Reinisch, W. (2015) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000350 · Cited by 84
Self-citation
Positioning Therapies in Ulcerative Colitis
Danese, S., Fiorino, G., & Peyrin‐Biroulet, L. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.01.017 · Cited by 83
Faecal Lactoferrin, Calprotectin, PMN-elastase, CRP, and White Blood Cell Count as Indicators for Mucosal Healing and Clinical Course of Disease in Patients with Mild to Moderate Ulcerative Colitis: Post Hoc Analysis of a Prospective Clinical Trial
Langhorst, J., Boone, J. H., Lauche, R., Rueffer, A., & Dobos, G. (2016) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjw044 · Cited by 83
The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
Holleran, G. E., Lopetuso, L. R., Petito, V., Graziani, C., Ianiro, G., McNamara, D. A., Gasbarrini, A., & Scaldaferri, F. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102020 · Cited by 88
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Mikami, Y., Tsunoda, J., Suzuki, S., Mizushima, I., Kiyohara, H., & Kanai∥, T. (2022) · Digestion · doi:10.1159/000527452 · Cited by 82
Gut microbiota in pathophysiology, diagnosis, and therapeutics of inflammatory bowel disease
Pandey, H., Jain, D., Tang, D. W. T., Wong, S. H., & Lal, D. (2023) · Intestinal Research · doi:10.5217/ir.2023.00080 · Cited by 95
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation - a placebo-controlled study
Watanabe, M., Nishino, H., Sameshima, Y., Ota, A., Nakamura, S., & Hibi∥, T. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12362 · Cited by 82
Thiopurines and Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease: A Meta-analysis
Jess, T., Lopez, A., Andersson, M., Beaugerie, L., & Peyrin‐Biroulet, L. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.019 · Cited by 82
Review article: acute severe ulcerative colitis – evidence‐based consensus statements
Chen, J., Andrews, J. M., Kariyawasam, V. C., Moran, N., Gounder, P., Collins, P. G. S., Walsh, A. J., Connor, S. J., Lee, T. W. T., Koh, C., et al. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13670 · Cited by 82
Randomised clinical study: discrepancies between patient‐reported outcomes and endoscopic appearance in moderate to severe ulcerative colitis
Jharap, B., Sandborn, W. J., Reinisch, W., D’Haens, G., Robinson, A. M., Wang, W., Huang, B., Lazar, A., Thakkar, R. B., & Colombel, J. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13387 · Cited by 81
Self-citation
‘Quality of Care’ Standards in Inflammatory Bowel Disease: A Systematic Review
Fiorino, G., Allocca, M., Chaparro, M., Coenen, S., Fidalgo, C. A., Younge, L., & Gisbert, J. P. (2018) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjy140 · Cited by 82
Induction of clinical and colonoscopic remission of mild–to–moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies
Sandborn, W. J., Danese, S., D’Haens, G., Moro, L., Jones, R., Bagin, R. G., HUANG, M. L., Ballard, E. D., Masure, J. A., & Travis, S. P. L. (2015) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13076 · Cited by 80
Self-citation
Second Korean guidelines for the management of ulcerative colitis
Choi, C. H., Moon, W., Kim, Y. S., Kim, E. S., Lee, B., Jung, Y., Yoon, Y. S., Lee, H., Park, D. I., & Han, D. S. (2017) · Intestinal Research · doi:10.5217/ir.2017.15.1.7 · Cited by 79
Acute severe ulcerative colitis: latest evidence and therapeutic implications
Dulai, P. S., & Jairath, V. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317742095 · Cited by 79
Efficacy and Safety of Induction Therapy With Calcineurin Inhibitors in Combination With Vedolizumab in Patients With Refractory Ulcerative Colitis
Pellet, G., Stéfanescu, C., Carbonnel, F., Peyrin‐Biroulet, L., Roblin, X., Allimant, C., Nachury, M., Nancey, S., Filippi, J., Altwegg, R., et al. (2018) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2018.08.081 · Cited by 79
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial
Rubin, D. T., Cohen, R. D., Sandborn, W. J., Lichtenstein, G. R., Axler, J. L., Riddell, R. H., Zhu, C., Barrett, A. C., Bortey, E. B., & Forbes, W. P. (2017) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjx032 · Cited by 80
Inflammatory bowel disease – non-biological treatment
Magro, F., Cordeiro, G., Dias, A. M., & Estevinho, M. M. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105075 · Cited by 77
Obesity in Inflammatory Bowel Disease: Gains in Adiposity despite High Prevalence of Myopenia and Osteopenia
Bryant, R. V., Schultz, C. G., Ooi, S., Goess, C., Costello, S. P., Vincent, A. D., Schoeman, S., Lim, A. H. W., Bartholomeusz, F. D., Travis, S. P. L., et al. (2018) · Nutrients · doi:10.3390/nu10091192 · Cited by 77
Self-citation
Colonoscopic evaluation in ulcerative colitis
Paine, E. R. (2014) · Gastroenterology report · doi:10.1093/gastro/gou028 · Cited by 77
Systematic review with meta‐analysis: the effect of tobacco smoking on the natural history of ulcerative colitis
To, N., Ford, A. C., & Gracie, D. J. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13663 · Cited by 77
Polymorphisms in the NF kB, TNF ‐alpha, IL ‐1beta, and IL ‐18 pathways are associated with response to anti‐ TNF therapy in Danish patients with inflammatory bowel disease
Bank, S., Julsgaard, M., Abed, O. K., Burisch, J. M., Brodersen, J. B., Pedersen, N. K., Gouliaev, A., Ajan, R., Rasmussen, D. N., Grauslund, C. H., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15187 · Cited by 77

Authors: Dignass, A., Lindsay, J. O., Sturm, A., Windsor, A., Colombel, J.-F., Allez, M., D'Haens, G., D'Hoore, A., Mantzaris, G., Novacek, G., Öresland, T., Reinisch, W., Sans, M., Stange, E., Vermeire, S., Travis, S., & Van Assche, G.
Affiliations: Agaplesion Markus Hospital (DE)
ORCID: Dignass, Axel
Lindsay, James O.
Sturm, Andreas
Windsor, Alastair
Mantzaris, Gerassimos
Novacek, Gottfried
Öresland, Tom
Reinisch, Walter
Sans, Miquel
Stange, Eduard
Travis, Simon
Venue: Journal of Crohn's and Colitis
Publisher: Oxford University Press (OUP)
Published: 2012-12-01
Volume: 6
Issue: 10
Pages: 991-1030
ISSN: 1873-9946 (ISSN-L)
1876-4479
DOI: 10.1016/j.crohns.2012.09.002
OpenAlex: W2120522488
Cited by: 1,548
References: 495
Citations by year: 2026: 11 · 2025: 25 · 2024: 53 · 2023: 76 · 2022: 115 · 2021: 152 · 2020: 168 · 2019: 161 · 2018: 156 · 2017: 146 · 2016: 165 · 2015: 136 · 2014: 121 · 2013: 57 · 2012: 4
FWCI: 60.30
Type: journal article
Language: en
Update notices: expression_of_concern (2022-01-24)
Open access: closed
Locations: Journal of Crohn s and Colitis (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
Keywords: ulcerative colitis, disease activity assessment
MeSH terms: Adrenal Cortex Hormones, Anti-Inflammatory Agents, Non-Steroidal, Colitis, Ulcerative, Humans, Immunosuppressive Agents, Tumor Necrosis Factor-alpha, Proctocolectomy, Restorative, Maintenance Chemotherapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 2: Current management

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks